logo
1 No-Brainer Artificial Intelligence Index Fund to Buy Right Now for Less Than $1,000

1 No-Brainer Artificial Intelligence Index Fund to Buy Right Now for Less Than $1,000

Globe and Mail2 days ago
Key Points
The Invesco QQQ Trust tracks the Nasdaq-100 and has exposure to many large AI players.
The fund is relatively inexpensive and has historically been a great long-term investment.
Buying the fund takes the guesswork out of trying to find stocks to ride the AI wave.
10 stocks we like better than Invesco QQQ Trust ›
Choosing winners in the fast-paced artificial intelligence (AI) race isn't always easy. Small AI start-ups can flame out quickly, while large companies run the risk of failing to keep up. Many investors opt to put their money in exchange-traded funds (ETFs) that track indexes to spread their money across a variety of companies.
One of the most popular ETFs with a lot of exposure to AI stocks is the Invesco QQQ Trust (NASDAQ: QQQ). The fund is designed to track the performance of the Nasdaq-100 index, and investing in it is a great way to benefit from the AI race without having to handpick the winners. Here's why.
1. It has exposure to the top AI companies
The Invesco QQQ Trust 's largest holdings are key players in the AI race and have already benefited -- and will likely continue to benefit -- as artificial intelligence grows. With this fund, you'll be invested in Microsoft, Nvidia, Amazon, and Alphabet, as well as other tech companies making big moves in AI.
Consider that Nvidia is one of the leading AI processor companies, with an estimated 95% of the AI processor market, and that Amazon and Microsoft are the two largest cloud computing companies offering advanced AI services to their customers.
All of this means that owning some of Invesco QQQ Trust will allow you to tap into AI processors, AI cloud services, artificial intelligence software, and likely whatever new AI products and services debut over the coming years.
2. ETFs are a great investment for beginners and experts alike
Whether you're just getting started in investing or you've been doing it for decades, ETFs are a great addition to any portfolio because they allow you to take some of the guesswork out of investing. Instead of poring over earnings calls and keeping tabs on how some macroeconomic news might affect the specific company you're invested in, you can instead spread your money across many companies all at once.
Plus, with the Invesco QQQ Trust, your investment will track the combined movements of the top 100 non-financial companies on the Nasdaq, many of which are the world's leading tech companies. As hundreds of billions of dollars are invested in AI in the coming years, this fund could continue to benefit from the strong artificial intelligence foundation that's already been established.
3. Easy liquidity and relatively low costs
Being the fifth-largest ETF, you won't have much of a problem buying or selling your shares of the Invesco QQQ Trust. A substantial amount of daily trading volumes and about $354 billion in assets under management mean that you'll easily find a buyer when you're ready to sell.
What's more, the fund has a relatively low expense ratio of just 0.20%. If you have $1,000 in the fund, your annual expense ratio is just $2 in fees. Since it's passively managed, the Invesco QQQ Trust charges far less than actively managed funds, which select stocks in an attempt to outperform specific indexes. Lower expense ratios help you keep more of the gains earned by the fund.
4. The Invesco QQQ Trust has been a top performer
No matter where you invest your money, there's always a risk that your investments won't perform well. And even if they do make significant gains when you own them, there's no guarantee they'll continue to do so.
But there's something to be said for funds that historically perform well over time. Since its launch in 1999, the Invesco QQQ Trust has gained nearly 1,000% while the S&P 500 is up about 400%. Of course, that doesn't mean it will continue growing at the same pace or even that the fund will outpace the broader market's returns in the coming years. Still, it's an indication the fund has, in the past, successfully benefited from large tech trends.
If you have $1,000 to spend right now and want to tap into artificial intelligence, this fund is a smart move. While there may be others with more focused exposure to AI, the Invesco QQQ Trust allows you to benefit from the largest technology companies on the Nasdaq, which could provide stability and long-term opportunity.
Should you invest $1,000 in Invesco QQQ Trust right now?
Before you buy stock in Invesco QQQ Trust, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why BigBear.ai Stock Skyrocketed Last Week
Why BigBear.ai Stock Skyrocketed Last Week

Globe and Mail

timean hour ago

  • Globe and Mail

Why BigBear.ai Stock Skyrocketed Last Week

Key Points stock surged 23.5% over the past week despite no major news for the business. The company's share price has continued to climb thanks to excitement surrounding defense-AI investments. explosive valuation has seen explosive gains lately despite little indication the company's outlook has seen big shifts. 10 stocks we like better than › (NYSE: BBAI) stock closed out this past week's trading with another run of big gains. The software and services company's share price climbed 23.5% from the previous week's market close amid a gain of 0.6% for the S&P 500 index. valuation surged again this past week, as investors continued to place bullish bets on companies with artificial intelligence (AI) tools tailored for the defense industry. The company's share price is now up 101% over the past month and 214% over the past three months. stock continues to surge despite no major news Even in the absence of apparent meaningful developments for the business, stock has continued to rally. The company's big valuation gains appear to be primarily connected to the defense-AI investment trend that has been hot in the market. Palantir has been a top defense-AI play and reached a new valuation high in this week's trading, and stock has often seen valuation moves that correspond with pricing action for the software leader. Some investors are betting that could emerge as a Palantir-like winner as demand for AI-powered defense software continues to increase. What's next for The massive valuation run up for stock appears to be out of step with the company's recent business performance and near-term outlook. Despite demand tailwinds in the AI industry, the company's revenue increased just 5% year over year in the last quarter. Growth is expected to accelerate in the second half of the company's current fiscal year, but management's midpoint target for annual sales growth of roughly 7.5% still raises valuation concerns following recent gains for the stock. While it's possible that continued acceleration for sales growth and margin improvements will pave the way for stock to see more explosive gains above its current valuation level, huge valuation gains in the absence of major news suggest that the company is a risky investment right now. Investors will get a closer look at the business on Aug. 11, when the company publishes its next quarterly report. Should you invest $1,000 in right now? Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025

Imagen Network (IMAGE) Enhances Social Customization with Grok AI Real-Time Processing Engines
Imagen Network (IMAGE) Enhances Social Customization with Grok AI Real-Time Processing Engines

Globe and Mail

time2 hours ago

  • Globe and Mail

Imagen Network (IMAGE) Enhances Social Customization with Grok AI Real-Time Processing Engines

New integration enables intelligent, adaptive content delivery and live personalization across decentralized social feeds. London, United Kingdom--(Newsfile Corp. - July 21, 2025) - Imagen Network, the decentralized AI social platform, has expanded its personalization infrastructure by embedding real-time processing engines powered by Grok AI. This enhancement delivers live content curation, emotion-aware feed structuring, and interactive customization for users across Ethereum, BNB Chain, and Solana. Delivering real-time AI customization for smarter, adaptive social interaction. To view an enhanced version of this graphic, please visit: The new processing layer enables Imagen to analyze behavior, engagement context, and sentiment cues in real time-allowing AI-generated suggestions, moderation tools, and creator recommendations to adapt fluidly to user preferences. Unlike static content systems, this engine ensures that every feed, profile, and post is dynamically tailored to its environment and audience. Grok AI's integration supports Imagen's modular social nodes by allowing communities to define their own personalization logic while benefiting from high-speed processing and contextual relevance. Whether delivering curated discussions, AI-enhanced visuals, or governance prompts, every element can now be tuned to individual and community identity. Imagen's real-time AI layer represents a leap in decentralized expressiveness-ensuring that social interaction is not only user-owned, but intelligent, responsive, and optimized for scale. About Imagen Network Imagen Network is a decentralized social platform that blends AI content generation with blockchain infrastructure to give users creative control and data ownership. Through tools like adaptive filters and tokenized engagement, Imagen fosters a new paradigm of secure, expressive, and community-driven networking. Media Contact Dorothy Marley KaJ Labs +1 707-622-6168 media@ Social Media Twitter Instagram

3 Monster Stocks in the Making to Buy Right Now
3 Monster Stocks in the Making to Buy Right Now

Globe and Mail

time3 hours ago

  • Globe and Mail

3 Monster Stocks in the Making to Buy Right Now

Key Points CRISPR Therapeutics is still in its early growth stage. Summit Therapeutics has plenty of upside potential remaining. Viking Therapeutics is targeting two monster markets. 10 stocks we like better than CRISPR Therapeutics › Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings. Three Motley Fool contributors think they've identified monster stocks in the making. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX). Image source: Getty Images. A promising company in its early growth stage David Jagielski (CRISPR Therapeutics): Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable in the long run. The gene editing market is still fairly small, but it has a lot of room to grow. Analysts from Grand View Research project that it will expand at a compound annual growth rate of more than 16% between now and 2030, when it will be worth $25 billion. As a leading company in the space, CRISPR Therapeutics is well positioned to benefit from future growth in this area of healthcare. The company, and its key development partner, Vertex Pharmaceuticals (NASDAQ: VRTX), already have an approved gene therapy treatment in Casgevy, which regulators have approved for both sickle cell disease and transfusion-dependent beta-thalassemia. The companies will share in the profits on the treatment (CRISPR will take 40%). Casgevy is still in its early growth stages. CRISPR is also working on developing treatments for type 1 diabetes and cardiovascular disease. While CRISPR remains unprofitable today, its future does look bright. It's a long road ahead for CRISPR Therapeutics, but with an encouraging pipeline and a lot of growth potential, this could be a monster healthcare stock in the making. The business is well funded with its cash and marketable securities as of the end of March totaling nearly $1.9 billion, putting it in an excellent position to continue investing in its research and development efforts. CRISPR can make for an excellent investment, but it's also one you'll need to be patient with. Still plenty of upside left for this stock Prosper Junior Bakiny (Summit Therapeutics): Few biotech companies have performed better than Summit Therapeutics over the past three years. The company's shares have soared by more than 2,000%, making early investors who held on significantly wealthier in the process. Here's the good news for those who are still considering the stock: There could be a massive upside left for Summit Therapeutics. Though the biotech generates no revenue and is unprofitable, it has one of the more promising pipeline products in the industry. Summit Therapeutics' leading candidate is a cancer medicine called ivonescimab, which it licensed out from Akeso Biopharma (OTC: AKES.F), a China-based drug developer. The medicine has been extensively tested in China, where it has already received approval in certain indications. One of ivonescimab's most promising markets is non-small cell lung cancer (NSCLC). In a phase 3 study in China, it went head-to-head against the market leader and the world's best-selling drug: Merck 's (NYSE: MRK) Keytruda. Ivonescimab emerged victorious, leading to a greater decrease in the risk of recurrence or death among NSCLC patients with a PD-L1 protein overexpression. Summit Therapeutics is conducting clinical studies to support approval in the U.S. and other regions. Furthermore, the biotech is likely to seek a series of approvals and label expansions over the years, based on the number of clinical trials and indications Akeso is targeting in China. Ivonescimab should easily become a blockbuster and generate strong sales for years. That's why it's not too late to invest in Summit Therapeutics. If ivonescimab achieves its full potential, Summit could deliver market-beating returns in the next five to 10 years and establish itself as a prominent player in the biotech industry. Targeting two monster markets Keith Speights (Viking Therapeutics): The big story for Viking Therapeutics is its experimental obesity drug VK2735. The company recently advanced a subcutaneous formulation of this candidate into late-stage clinical testing after announcing highly encouraging results from a phase 2 study last year. Viking is also evaluating an oral version of VK2735 in a separate phase 2 clinical trial, and it expects to report results from that study later in 2025. In addition, the drugmaker plans to initiate a clinical study for a monthly maintenance version of subcutaneous VK2735 in the coming months. Morgan Stanley Research projects that the global obesity drug market could reach $150 billion by 2035. Viking could be in a great position to claim a nice chunk of that market if VK2735 fulfills its potential. Obesity isn't the only big market that the company is targeting, though. In 2023, Viking reported positive results from a phase 2 study of VK2809 in treating metabolic-associated steatohepatitis (MASH), a chronic liver disease also known as nonalcoholic steatohepatitis (NASH). The company is seeking a partner to advance VK2809 into late-stage testing, so it can dedicate its financial resources exclusively to VK2735 for now. Grand View Research predicts the MASH/NASH market could hit $33.8 billion by 2030, so that's a nice opportunity. A clinical trial flop for VK2735 and/or a failure to find a partner for VK2809 could prevent Viking from becoming a monster stock. However, I think the company's chances look pretty good. I also wouldn't be surprised if a larger drugmaker swoops in to acquire Viking. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store